Aurinia Pharmaceuticals(US:AUPH) Zacks Investment Research·2024-05-02 12:11分组1 - Aurinia Pharmaceuticals reported a quarterly loss of $0.03 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.17, and an improvement from a loss of $0.18 per share a year ago, resulting in an earnings surprise of 82.35% [1] - The company generated revenues of $50.3 million for the quarter ended March 2024, exceeding the Zacks Consensus Estimate by 8.65%, and showing a year-over-year increase from $34.41 million [1] - Over the last four quarters, Aurinia has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [1] 分组2 - Aurinia shares have declined approximately 42.2% since the beginning of the year, contrasting with the S&P 500's gain of 5.2% [2] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $54.19 million, and for the current fiscal year, it is -$0.06 on revenues of $225.59 million [4] - The Medical - Drugs industry, to which Aurinia belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [4]